top of page

WHERE DOES THE MONEY GO?

Our mission?

To fund Australia’s brightest and most innovative medical researchers and clinicians in their efforts to provide all cancer patients with ‘precision’ cancer treatments and to help create access to new techniques and integrated comprehensive data for medical researchers and physicians.

Our aspiration?

To ensure precision treatment for ALL new cancer patients, whatever the cancer, regardless of location, age, income or status. It is our vision that patients are offered the right treatment, first time, every time. And that, at the cusp of a post-genome revolution, Australia can show the world how precision medicine is done.

What is 'precision' medicine?

Every cancer is different for every body. Precision Medicine, using current, widely available technologies, offers the tantalising prospect of analysing a tissue sample and treating cancer with the right drug, first time, every time. This increases positive treatment outcomes, decreases treatment times and saves countless millions on ineffective treatments. The data from each sample also helps us further map cancer genetically.

Artboard 1 copy2.png

THE RIGHT TREATMENT FOR EVERY CANCER PATIENT

Prof. David Thomas Director Centre for Molecular Oncology, School of Biomedical Sciences, University of New South Wales; Chief Executive Officer Omico (Australian Genomic Cancer Medicine Centre); Laboratory Head Genomic Cancer Medicine, Garvan Institute of Medical Research

SCIENCE THANKS LOVE YOUR SISTER

Dr. Belinda Yeo

Clinician Scientist, Oliva Newton-John Cancer Research Institute

Artboard 1 copy2.png

HERE ARE THE INCREDIBLE CANCER VANQUISHING PROJECTS WE SUPPORT. 

THE CONNIE JOHNSON BREAST CANCER RESEARCH LABORATORY

2013 - extant

INSTITUTION:

The Garvan Institute of Medical Research

 

CHIEF RESEARCHERS:

Assoc. Prof. Elgene Lim & Assoc. Prof. Alex Swarbrick

 

SYNOPSIS:

The Connie Johnson Laboratory performs clinically focused laboratory research, aiming to better understand the heterogeneity in breast cancer, and identifying novel ways to treat breast cancer.

IMPROVING CANCER OUTCOMES IN RURAL AND REMOTE AUSTRALIA

2023 - 2026

INSTITUTION:

Macquarie University

 

CHIEF RESEARCHERS:

Prof. Howard Gurney; Nicola Chapman; A/Prof. Boe Rambaldini; Dr. Kylie Gwynne

 

SYNOPSIS:

Improving cancer outcomes in rural and remote Australia: developing effective, sustainable and scalable models for clinical trials.

THE ZERO CHILDHOOD CANCER PROGRAM

2021 - extant

INSTITUTION:

An initiative of Children’s Cancer Institute and Kids Cancer Centre at Sydney Children’s Hospital

 

CHIEF RESEARCHER:

Prof. Glenn Marshall AM

 

SYNOPSIS:

The Zero Childhood Cancer program aims to one day be able to provide a personalised treatment plan for every child.

CURING THE INCURABLE: PATIENT-CENTRED DIAGNOSTICS GUIDING THE SELECTION OF THERAPIES FOR METASTATIC BREAST CANCER

2020 - 2023

INSTITUTIONS:

Olivia Newton-John Cancer Research Institute (ONJCRI) & La Trobe University

 

CHIEF RESEARCHERS:

Dr Belinda Yeo and Dr Delphine Merino

 

SYNOPSIS:

A formal translational study to demonstrate the value of analysing patient samples in both early stage and advanced breast cancer, ...

SHARE, COLLABORATE & CURE: THE MACQUARIE UNIVERSITY CANCER BIOBANK

2020 - 2023

INSTITUTION:

Macquarie University

 

CHIEF RESEARCHER: 

Dr. Helen Rizos

 

SYNOPSIS:

A bold plan to provide a library of viable cancer specimens and genomic data across many cancer types.

PRECISION TARGETING OF BREAST CANCER FIBROSIS TO BOOST EFFICIENCY OF CHEMOTHERAPY

2021 - 2023

INSTITUTION:

The Garvan Institute of Medical Research

 

CHIEF RESEARCHER: 

Dr. Thomas Cox

 

SYNOPSIS:

Dr Cox and his team have generated exciting data to identify a critical enzyme (Peroxidasin) which is involved in the formation of the scar-like matrix in breast cancer.

MORE PRECISE RISK ESTIMATES FOR EARLY-STAGE BREAST CANCER

2021 - 2023

INSTITUTIONS:

The University of Melbourne/Peter MacCallum Cancer Centre

 

CHIEF RESEARCHER:

Dr. Peter Savas

 

SYNOPSIS:

This research will study how different changes in the DNA in the tumours of over 11,000 patients affect the chance of the cancer coming back after surgery.

IDENTIFYING TARGETS ON MYELOID CELLS TO DESIGN PERSONALISED COMBINATION IMMUNOTHERAPIES FOR TRIPLE-NEGATIVE BREAST CANCER

2021 - 2023

INSTITUTIONS:

Olivia Newton-John Cancer Research Institute (ONJCRI) & La Trobe University

 

CHIEF RESEARCHER:

Prof. Robin Anderson

 

SYNOPSIS:

Targeting pro-tumour immune cells to improve response to immunotherapy for triple-negative breast cancer patients.

A NEW IMMUNOTHERAPY APPROACH TO TARGET TRIPLE-NEGATIVE BREAST CANCER

2021 - 2023

INSTITUTION:

Queensland Institute of Medical Research Berghofer

 

CHIEF RESEARCHER:

Prof. Kum Kum Khanna

 

SYNOPSIS:

This research will improve our knowledge about the factors that inhibit growth and recurrence of breast cancer, which is critical to unlocking better treatment strategies. ...

FINDING TREATMENT FOR RIBOCICLIB RESISTANT BREAST CANCER USING PERSONALISED MEDICINE AND BIOSENSOR TECHNOLOGY

2021 - 2023

INSTITUTION:

The Garvan Institute of Medical Research

 

CHIEF RESEARCHER:

Prof. Paul Timpson

 

SYNOPSIS:

Our ultimate goal is to have the design of an early phase clinical trial conceptually established and pre-clinically validated within the duration of this grant.

OVERCOMING NETWORK REMODELLING TO IDENTIFY NEW THERAPEUTIC STRATEGIES FOR POOR PROGNOSIS BREAST CANCER

2020 - 2023

INSTITUTION:

Monash University

 

CHIEF RESEARCHER:

Dr. Lan Nguyen

 

SYNOPSIS:

The study will employ the use of novel machine learning techniques (data science) to develop predictive markers...

USING POLYGENIC RISK MODIFICATION TO IMPROVE BREAST CANCER PREVENTION: THE PRIMO TRIAL.

2020 - 2023

INSTITUTION:

Peter MacCallum Cancer Centre

 

CHIEF RESEARCHER:

A/Prof. Paul James

 

SYNOPSIS:

Genomic testing will be used to identify women who can benefit the most from preventative strategies. Outcomes from this study will lead to the implementation of personalised risk management.

FULL-TIME RESEARCH ASSISTANT FOR A THREE-YEAR PERSONALISED BREAST CANCER RESEARCH PROJECT

2019 - 2022

INSTITUTION:

Olivia Newton-John Cancer Research Institute (ONJCRI)

 

CHIEF RESEARCHER:

Prof. Robin Anderson

 

SYNOPSIS:

A model to create a living breast cancer biobank.

STOPPING CANCER CELLS’ PRO-SURVIVAL MECHANISMS IN TRIPLE-NEGATIVE BREAST CANCER

2019 - 2020

INSTITUTION:

The University of Sydney

 

CHIEF RESEARCHER:

Dr. Sumit Sahni

 

SYNOPSIS:

Development of novel therapy targeting autophagy against Triple-Negative Breast Cancers (TNBCs).

COMBATING AGGRESSIVE BREAST CANCER WITH A NEW TREATMENT

2019 - 2021

INSTITUTION:

Olivia Newton-John Cancer Research Institute (ONJCRI)

 

CHIEF RESEARCHER:

Prof. Matthias Ernst

 

SYNOPSIS:

Targeting Interleukin-11-signalling for treatment of Metastatic Breast Cancer.

DEVELOPING PERSONALISED TREATMENTS FOR BREAST CANCERS WITH POOR PROGNOSIS

2019 - 2020

INSTITUTION: Monash University

 

CHIEF RESEARCHER:

Prof. Roger Daly

 

SYNOPSIS:

A comprehensive evaluation of the TAOK2 protein and its role in aggressive breast cancer.

bottom of page